Finished product reference
Trimetazidine
Tablet, Film Coated, Extended Release · Oral · 35 mg
- List code
- 12115
- Pharmacologic class
- Anti-anginal agent (metabolic modulator; partial fatty acid oxidation inhibitor)
What it is and how it works
Trimetazidine inhibits mitochondrial long-chain 3-ketoacyl-CoA thiolase, shifting myocardial energy metabolism from fatty acid oxidation towards glucose oxidation, which requires less oxygen per unit of ATP produced. This preserves energy metabolism in ischaemic cells without affecting heart rate or blood pressure.
Indications
Add-on symptomatic treatment of stable angina pectoris in adults inadequately controlled by, or intolerant of, first-line anti-anginal therapies.
Dosage and administration (summary)
Orally, 35 mg modified-release twice daily with meals (or 20 mg immediate-release three times daily); 35 mg once daily in moderate renal impairment and in elderly patients with reduced renal function.
Contraindications
Parkinson’s disease, parkinsonian symptoms, tremor, restless legs syndrome and other related movement disorders; severe renal impairment (creatinine clearance below 30 mL/min).
Warnings and precautions
Can cause or worsen parkinsonian symptoms, tremor, gait instability and falls; discontinue permanently if movement disorders occur. It is not a treatment for acute angina attacks or unstable angina. Use with caution in moderate renal impairment and in the elderly.
Pregnancy
Avoid in pregnancy as a precaution owing to lack of data.
Storage and supply
Store below 25 °C.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.